TY - JOUR
T1 - TANGO2
T2 - expanding the clinical phenotype and spectrum of pathogenic variants
AU - Dines, Jennifer N.
AU - Golden-Grant, Katie
AU - LaCroix, Amy
AU - Muir, Alison M.
AU - Cintrón, Dianne Laboy
AU - McWalter, Kirsty
AU - Cho, Megan T.
AU - Sun, Angela
AU - Merritt, J. Lawrence
AU - Thies, Jenny
AU - Niyazov, Dmitriy
AU - Burton, Barbara
AU - Kim, Katherine
AU - Fleming, Leah
AU - Westman, Rachel
AU - Karachunski, Peter
AU - Dalton, Joline
AU - Basinger, Alice
AU - Ficicioglu, Can
AU - Helbig, Ingo
AU - Pendziwiat, Manuela
AU - Muhle, Hiltrud
AU - Helbig, Katherine L.
AU - Caliebe, Almuth
AU - Santer, René
AU - Becker, Kolja
AU - Suchy, Sharon
AU - Douglas, Ganka
AU - Millan, Francisca
AU - Begtrup, Amber
AU - Monaghan, Kristin G.
AU - Mefford, Heather C.
N1 - Funding Information:
We thank the families, GeneDx, and practitioners for their participation and collaboration in this case series. Research reported in this publication was supported in part by a grant from the National Institutes of Health (NS069605 to H.C.M.), and the National Institute of General Medical Sciences of the National Institutes of Health Postdoctoral Training Program in Medical Genetics (5T32GM007454 to J.N.D.). This work was also supported by intramural funds of the University of Kiel (I.H.), the German Research Foundation (HE5415/3-1 to I.H.) within the EuroEPINOMICS framework of the European Science Foundation, and individual grants by the German Research Foundation (D.F. G., HE5415/5-1, HE5415/6-1 to I.H.).
Publisher Copyright:
© 2018, American College of Medical Genetics and Genomics.
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Purpose: TANGO2-related disorders were first described in 2016 and prior to this publication, only 15 individuals with TANGO2-related disorder were described in the literature. Primary features include metabolic crisis with rhabdomyolysis, encephalopathy, intellectual disability, seizures, and cardiac arrhythmias. We assess whether genotype and phenotype of TANGO2-related disorder has expanded since the initial discovery and determine the efficacy of exome sequencing (ES) as a diagnostic tool for detecting variants. Methods: We present a series of 14 individuals from 11 unrelated families with complex medical and developmental histories, in whom ES or microarray identified compound heterozygous or homozygous variants in TANGO2. Results: The initial presentation of patients with TANGO2-related disorders can be variable, including primarily neurological presentations. We expand the phenotype and genotype for TANGO2, highlighting the variability of the disorder. Conclusion: TANGO2-related disorders can have a more diverse clinical presentation than previously anticipated. We illustrate the utility of routine ES data reanalysis whereby discovery of novel disease genes can lead to a diagnosis in previously unsolved cases and the need for additional copy-number variation analysis when ES is performed.
AB - Purpose: TANGO2-related disorders were first described in 2016 and prior to this publication, only 15 individuals with TANGO2-related disorder were described in the literature. Primary features include metabolic crisis with rhabdomyolysis, encephalopathy, intellectual disability, seizures, and cardiac arrhythmias. We assess whether genotype and phenotype of TANGO2-related disorder has expanded since the initial discovery and determine the efficacy of exome sequencing (ES) as a diagnostic tool for detecting variants. Methods: We present a series of 14 individuals from 11 unrelated families with complex medical and developmental histories, in whom ES or microarray identified compound heterozygous or homozygous variants in TANGO2. Results: The initial presentation of patients with TANGO2-related disorders can be variable, including primarily neurological presentations. We expand the phenotype and genotype for TANGO2, highlighting the variability of the disorder. Conclusion: TANGO2-related disorders can have a more diverse clinical presentation than previously anticipated. We illustrate the utility of routine ES data reanalysis whereby discovery of novel disease genes can lead to a diagnosis in previously unsolved cases and the need for additional copy-number variation analysis when ES is performed.
KW - developmental delay DNA copy-number variation
KW - epilepsy
KW - exome sequencing
KW - intragenic deletion
UR - http://www.scopus.com/inward/record.url?scp=85053697540&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85053697540&partnerID=8YFLogxK
U2 - 10.1038/s41436-018-0137-y
DO - 10.1038/s41436-018-0137-y
M3 - Article
C2 - 30245509
AN - SCOPUS:85053697540
VL - 21
SP - 601
EP - 607
JO - Genetics in Medicine
JF - Genetics in Medicine
SN - 1098-3600
IS - 3
ER -